Insulin resistance in HIV-related lipodystrophy

Current Hypertension Reports

Volumn 5, Issue 2, 2003, Pages 117-121

  Mikhail, Nasser ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; INDINAVIR; INSULIN; LEPTIN; LIPID; METFORMIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DEATH; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENE EXPRESSION; HIV ASSOCIATED LIPODYSTROPHY; HORMONE ACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; METABOLIC DISORDER; REVIEW; RISK FACTOR; TISSUE DISTRIBUTION; ADIPOCYTE; BLOOD; DRUG EFFECT; METABOLISM;

ADIPOCYTES; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPIDS;

EID: 0037675050     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0067-0     Document Type: Review

References (38)

1. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Yanovski JA, Miller KD, Kino T, et al.: Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999, 84:1925-1931.
3. Martinez E, Mocroft A, Garcia-Viejo MA, et al.: Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-597.
4. Gervasoni C, Ridolfo AL, Trifiro G, et al.: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
5. Matthews DR, Hosker JP, Rudenski AS, et al.: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-417.
6. Saad MF, Anderson RL, Laws A, et al.: A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 1994, 43:1114-1121.
7. Hommes M, Romijn J, Endert E, et al.: Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
8. Hellerstein MK, Grunfeld C, Wu K et al.: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993, 76:559-565.
9. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-infected patients. AIDS 1998, 12:F167-F173.
10. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
11. Mynarcik DC, McNurlan MA, Steigbigel RT et al.: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312-321.
12. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
13. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:11-18.
14. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
15. Petit JM, Duong M, Dullivard L, et al.: HIV-1 Protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: A longitudinal study. Horm Metabol Res 2000, 32:367-372.
16. Saint-Marc T, Partisani M, Poizot-Martin I, et al.: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
17. Saint-Marc T, Partisani M, Poizot-Martin I, et al.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14:37-49.
18. Chene G, Angelin E, Cotte L, et al.: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002, 34:649-657.
19. Hadigan C, Corcoran C, Stanley T, et al.: Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000, 85:35-41.
20. Hadigan C, Miller K, Corcoran C, et al.: Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84:1932-1937.
21. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
22. Murata H, Hruz PW, Mueckler M: Indinavir inhibits the glucose transporter isoform, Glut 4 at physiologic concentrations. AIDS 2002, 16:859-863.
23. Caron M, Auclair M, Vigouroux C, et al.: The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
24. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994, 91:4854-4858.
25. Ledru E, Christeff N, Patey O, et al.: Alteration of tumor necrosis factor-a T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000, 95:3191-3198.
26. Ebihara K, Ogawa Y, Masuzaki H, et al.: Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001, 50:1440-1448.
27. Oral EA, Simha V, Ruiz E, et al.: Leptin replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570-578.
28. Vigouroux C, Gharakhanian S, Salhi Y, et al.: Diabetes, insulin resistance, and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999, 25:225-232.
29. Bastard J, Caron M, Vidal H, et al.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026-1031.
30. Klein D, Hurley LB, Quesenberry CP, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471-477.
31. Currier JS, Boyd F, Kawabata H, et al.: Diabetes mellitus in HIV-infected individuals [poster 677-T]. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle. February 22-25, 2002.
32. Holmberg S, Moorman A, Tong T, et al., for the HIV Outpatient Study (HOPS) Investigators: Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients [poster 698-T]. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle. February 22-25, 2002.
33. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome. A randomized controlled trial. JAMA 2000, 284:472-477.
34. Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central obesity in patients receiving effective protease inhibitor therapy [letter]. AIDS 1999, 13:1000-1002.
35. Walli R, Michl CM, Muhlbayer D, et al.: Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med 2000, 199:253-262.
36. Hatano H, Miller KD, Yoder CP, et al.: Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000, 14:1935-1942.
37. Wanke C, Gerrior J, Kantaros J, et al.: Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999, 13:2099-2103.
38. Fichtenbaum C, Gerber J, Rozenkranz S, et al.: Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors [abstract LB6]. In Programs and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000:236.